false 0001625101 0001625101 2024-01-09 2024-01-09
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): January 9, 2024
 
Pulse Biosciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
     
Delaware
001-37744
46-5696597
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
 
3957 Point Eden Way 
Hayward, California 94545
(Address of Principal Executive Offices) (Zip Code)
 
510-906-4600
(Registrant’s Telephone Number, Including Area Code)
 
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common stock, $0.001 par value per share
PLSE
The Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 7.01
Regulation FD Disclosure.
 
On January 9, 2024, Pulse Biosciences, Inc., a Delaware corporation (the “Company”), posted an updated investor presentation on its website. The updated investor presentation (the “Investor Deck”) discloses recent progress in the Company’s ongoing product development programs relating to its proprietary CellFX™ nsPFA™ 360 Cardiac Catheter, its CellFX nsPFA Cardiac Clamp, and its CellFX nsPFA Percutaneous Electrode. The Company expects to use this updated investor presentation, either in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others. A copy of the Investor Deck is attached hereto as Exhibit 99.1 and incorporated by reference in this Item 7.01. The Investor Deck is also available on the Company’s website at www.pulsebiosciences.com under “Investors.”
 
Except for the Investor Deck, information contained on, or accessible through, the Company’s website is not a part of, and is not incorporated by reference in, this Current Report on Form 8-K. The information contained in the Investor Deck itself is summary information only and it contains forward looking statements that are subject to risks and uncertainties, including those set forth in the Company’s filings with the U.S. Securities and Exchange Commission. Also, the information in the Investor Deck is as of January 2024, and the Company undertakes no obligation to publicly update or revise the information contained in the Investor Deck or this Item 7.01, except as required by law, although it made do so from time to time.
 
The information contained in Item 7.01 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly stated otherwise.
 
Item 9.01
Financial Statements and Exhibits.
 
(d) Exhibits
 
Exhibit
Number
Description
   
99.1
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
PULSE BIOSCIENCES, INC.
  
     
     
Date: January 9, 2024
By:
/s/ Kevin P. Danahy
  
   
Kevin P. Danahy
  
   
President and Chief Executive Officer
(Principal Executive and Principal Financial Officer)
  
 
 

Exhibit 99.1

 

 

 

b01.jpg

 

 

 
 
b02.jpg

 

 
 
b03.jpg

 

 
 
b04.jpg

 

 
 
b05.jpg

 

 
 
b06.jpg

 

 
 
b07.jpg

 

 
 
b08.jpg

 

 
 
b09.jpg

 

 
 
b10.jpg

 

 
 
b11.jpg

 

 
 
b12.jpg

 

 
 
b13.jpg

 

 
 
b14.jpg

 

 
 
b15.jpg

 

 
 
b16.jpg

 

 
 
b17.jpg

 

 
v3.23.4
Document And Entity Information
Jan. 09, 2024
Document Information [Line Items]  
Entity, Registrant Name Pulse Biosciences, Inc.
Document, Type 8-K
Document, Period End Date Jan. 09, 2024
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-37744
Entity, Tax Identification Number 46-5696597
Entity, Address, Address Line One 3957 Point Eden Way
Entity, Address, City or Town Hayward
Entity, Address, State or Province CA
Entity, Address, Postal Zip Code 94545
City Area Code 510
Local Phone Number 906-4600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock
Trading Symbol PLSE
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001625101
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Pulse Biosciences Charts.
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Pulse Biosciences Charts.